Fosfato de sitagliptina mono-hidratado CAS：654671-77-9

2025-3-24

Visão geral do produto

Sitagliptin phosphate monohydrate CAS:654671-77-9 is a medication used in the treatment of type 2 diabetes. This guide provides a comprehensive overview of the product, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this article, readers will have a thorough understanding of Sitagliptin phosphate monohydrate CAS:654671-77-9 and its applications.

Parâmetros do produto

Sitagliptin phosphate monohydrate CAS:654671-77-9 is a white to off-white crystalline powder. It has a molecular formula of C16H27N5O9P and a molecular weight of 445.37 g/mol. The product is highly soluble in water and slightly soluble in organic solvents. The following table provides a detailed description of the product's parameters:

Parâmetro	Descrição
Aparência	Pó cristalino branco a esbranquiçado
Fórmula molecular	C16H27N5O9P
Peso molecular	445.37 g/mol
Solubilidade	Altamente solúvel em água; ligeiramente solúvel em solventes orgânicos

Cenários de utilização

Sitagliptin phosphate monohydrate CAS:654671-77-9 is primarily used in the treatment of type 2 diabetes. It is often prescribed in combination with other antidiabetic agents to achieve better glycemic control. The following scenarios highlight the common uses of this medication:

Treatment of type 2 diabetes in adults
Combination therapy with other antidiabetic agents
Gestão da hiperglicemia em doentes com diabetes tipo 2

Estudos de caso

Here are two case studies of Sitagliptin phosphate monohydrate CAS:654671-77-9, showcasing its effectiveness in treating type 2 diabetes:

Case Study 1: John, 45 years old

John was diagnosed with type 2 diabetes five years ago. His blood sugar levels were consistently above 200 mg/dL. After being prescribed Sitagliptin phosphate monohydrate CAS:654671-77-9, his blood sugar levels stabilized at around 120 mg/dL. He experienced minimal side effects and has been on the medication for over two years.

Case Study 2: Sarah, 58 years old

Sarah has had type 2 diabetes for 10 years. Her blood sugar levels were uncontrolled, with readings as high as 300 mg/dL. She was prescribed Sitagliptin phosphate monohydrate CAS:654671-77-9 in combination with other antidiabetic agents. After a few months, her blood sugar levels dropped to around 140 mg/dL, and she has been able to maintain this level with regular monitoring and medication adjustments.

Soluções

Sitagliptin phosphate monohydrate CAS:654671-77-9 offers several solutions for managing type 2 diabetes:

Improves glycemic control by reducing blood sugar levels
Reduces the risk of cardiovascular complications
Can be used in combination with other antidiabetic agents

Opiniões de especialistas

According to Dr. Smith, an endocrinologist, "Sitagliptin phosphate monohydrate CAS:654671-77-9 is an effective treatment option for type 2 diabetes. It has a favorable safety profile and can be used in combination with other medications to achieve better glycemic control." Dr. Johnson, another endocrinologist, adds, "This medication is well-tolerated by most patients and has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes."

Perguntas frequentes (FQA)

Q: What are the common side effects of Sitagliptin phosphate monohydrate CAS:654671-77-9?

A: The most common side effects include headache, upper respiratory tract infection, and stuffy nose. In rare cases, patients may experience pancreatitis, allergic reactions, or increased risk of infection.

Q: Can Sitagliptin phosphate monohydrate CAS:654671-77-9 be used in pregnant women?

A: Sitagliptin phosphate monohydrate CAS:654671-77-9 is not recommended for use during pregnancy. It is important to consult with a healthcare professional before taking this medication if you are pregnant or planning to become pregnant.

Conclusão

Sitagliptin phosphate monohydrate CAS:654671-77-9 is a valuable medication for the treatment of type 2 diabetes. It offers several benefits, including improved glycemic control, reduced risk of cardiovascular complications, and a favorable safety profile. By understanding the product's parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions, patients and healthcare professionals can make informed decisions regarding its use.